Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Advancis Pharmaceutical Corporation |
---|---|
Information provided by: | Advancis Pharmaceutical Corporation |
ClinicalTrials.gov Identifier: | NCT00095368 |
The purpose of the this study is to evaluate the safety of efficacy of APC-111 775 mg MP tablet once daily dosing for 7 days for treating patients with strep throat. The evaluation will look to confirm if APC-111 eliminates the bacterial infection (Streptococcus pyogenes).
Condition | Intervention | Phase |
---|---|---|
Pharyngitis Tonsillitis |
Drug: Amoxicillin Pulsatile Release Multiparticulate Tablet (drug) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Randomized, Double-Blind, Double-Dummy Multicenter Study to Evaluate the Efficacy and Safety of 775 mg APC-111 MP Tablet QD for 7 Days vs Penicillin VK 250 mg QID for 10 Days in Patients With Streptococcus Pyogenes |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 111.301 |
Study First Received: | November 3, 2004 |
Last Updated: | December 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00095368 |
Health Authority: | United States: Food and Drug Administration |
Pharyngitis Tonsillitis |
Amoxicillin Penicillin V Otorhinolaryngologic Diseases Respiratory Tract Diseases Respiratory Tract Infections |
Streptococcal Infections Tonsillitis Stomatognathic Diseases Pharyngitis Pharyngeal Diseases |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Pharmacologic Actions |